Shares in Aarti Drugs (NSI:AARTIDRUGS) are currently trading at 1743.1 but a key question for investors is how the economic uncertainty caused by Covid-19 will affect the price. The answer comes down to judging whether Aarti Drugs is w...
AARTIDRUGS — Aarti Drugs Share Price
- IN₹57.19bn
- IN₹60.14bn
- IN₹21.55bn
Momentum
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | 16.45 | ||
PEG Ratio (f) | |||
EPS Growth (f) | |||
Dividend Yield (f) | 0.24% |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | |||
Price to Tang. Book | |||
Price to Free Cashflow | |||
Price to Sales | |||
EV to EBITDA |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | |||
Return on Equity | |||
Operating Margin |
Financial Summary
Year End 31st Mar | Unit | 2017 | 2018 | 2019 | 2020 | 2021 | 2022E | 2023E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | IN₹m | 12,880.8 | 12,625.69 | 15,609.41 | 18,060.88 | 21,547.8 | 25,031.5 | 31,022 | 13.68% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | +18.61 | +3.69 | +5.91 | +60.22 | +103.11 | +8.24 | +40.09 | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Latest News & Insights for AARTIDRUGS
Quality and momentum are highly prized among investors looking for reliable investment ideas. That's because good quality stocks tend to be resilient, cash-generating businesses that can compound investment returns over time. And those...
Shares in Aarti Drugs (NSI:AARTIDRUGS) are currently trading at 1287.55 but the question for investors is how much the market chaos of 2020 will impact its share price. The answer comes down to judging whether Aarti Drugs is well place...
The Aarti Drugs (NSI:AARTIDRUGS) share price is currently trading at 1000. But given the volatile market conditions and uncertain economic outlook, the question now is what the future holds for it. To try and predict where the Aarti Dr...
Despite the market volatility, shares in Aarti Drugs (NSI:AARTIDRUGS) have been in an uptrend in recent months. The question now for investors is whether that price strength will continue. Finding stocks with the potential to break-out...
Profile Summary
Aarti Drugs Limited is a pharmaceutical company. The Company offers active pharmaceutical ingredients (APIs) in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antifungals, antibiotic, antidiabetic, sedative and vitamins. Its products under APIs include Aceclofenac, Diclofenac Potassium, Diclofenac Diethylamine, Clopidogrel Bisulphate and Telmisartan. Its pharma intermediates include Antiprotozoal, Celecoxib, Antibiotic, Clopidogrel, Diclofenac, Ketoconazole, Nimesulide, Raloxifene, Zolpidem and Telmisartan. It also offers specialty chemicals, such as Benzene Sulphonamide, Benzene Sulphonic acid methyl ester, Benzene Sulphonyl chloride, Methyl Nicotinate, N-Methyl Methane Sulphonamide, Ortho para toluene Sulphonamide, Ortho/para toluene Sulphonic acid methyl ester, Para chloro benzene sulphonamide, Para Toluene Sulphonic acid methyl ester and Para Toluene Sulphonyl Chloride. Pinnacle Life Science Private Limited is the subsidiary of the Company.
Directors
- Prakash Patil CHM (68)
- Chandrakant Gogri NEC (74)
- Rushikesh Deole
- Harshit Savla MDR (52)
- Rashesh Gogri EDR (41)
- Uday Patil (52)
- Harit Pragji Shah (51)
- Rajendra Gogri NED (55)
- Priti Savla (37)
- Krishnacharya Akamanchi (62)
- Vilas Gaikar (54)
- Ramdas Gandhi (82)
- Navin Shah (54)
- Bhavesh Vora (48)
- Last Annual
- March 31st, 2021
- Last Interim
- June 30th, 2021
- Incorporated
- September 28th, 1984
- Public Since
- May 12th, 1993
- No. of Shareholders
- 177,366
- No. of Employees
- 1,239
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- National Stock Exchange of India
- Shares in Issue
- 92,600,000
- Address
- Block No1 & 12 To 16, MUMBAI, 400022
- Web
- https://www.aartidrugs.co.in/
- Phone
- +91 2224019025
- Auditors
- Kirtane & Pandit LLP
Latest News for AARTIDRUGS
Upcoming events for AARTIDRUGS
Q2 2022 Aarti Drugs Ltd Earnings Release
Similar to AARTIDRUGS
AAREY DRUGS & PHARMACEUTICALS ORD
National Stock Exchange of India
ABBOTT INDIA ORD
National Stock Exchange of India
ALEMBIC ORD
National Stock Exchange of India
ALEMBIC PHARMACEUTICALS ORD
National Stock Exchange of India
ALKEM LABORATORIES ORD
National Stock Exchange of India
FAQ
As of Today at 11:30 UTC, shares in Aarti Drugs are trading at IN₹617.60. This share price information is delayed by 15 minutes.
Shares in Aarti Drugs last closed at IN₹617.60 and the price had moved by +4.37% over the past 365 days. In terms of relative price strength the Aarti Drugs share price has underperformed the S&P BSE 100 Index by -28.33% over the past year.
The overall consensus recommendation for Aarti Drugs is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
The Aarti Drugs dividend yield is 0.4% based on the trailing twelve month period.
Last year, Aarti Drugs paid a total dividend of IN₹2.50, and it currently has a trailing dividend yield of 0.4%. We do not have any data on when Aarti Drugs is to next pay dividends.
We do not have data on when Aarti Drugs is to next pay dividends. The historic dividend yield on Aarti Drugs shares is currently 0.4%.
To buy shares in Aarti Drugs you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of IN₹617.60, shares in Aarti Drugs had a market capitalisation of IN₹57.19bn.
Here are the trading details for Aarti Drugs:
- Country of listing: India
- Exchange: NSI
- Ticker Symbol: AARTIDRUGS
Based on an overall assessment of its quality, value and momentum Aarti Drugs is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Aarti Drugs is IN₹862.00. That is 39.57% above the last closing price of IN₹617.60.
Analysts covering Aarti Drugs currently have a consensus Earnings Per Share (EPS) forecast of IN₹32.55 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Aarti Drugs. Over the past six months, its share price has underperformed the S&P BSE 100 Index by -13.21%.
As of the last closing price of IN₹617.60, shares in Aarti Drugs were trading -12.51% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Aarti Drugs PE ratio based on its reported earnings over the past 12 months is 19.91. The shares last closed at IN₹617.60.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Aarti Drugs' management team is headed by:
- Prakash Patil - CHM
- Chandrakant Gogri - NEC
- Rushikesh Deole -
- Harshit Savla - MDR
- Rashesh Gogri - EDR
- Uday Patil -
- Harit Pragji Shah -
- Rajendra Gogri - NED
- Priti Savla -
- Krishnacharya Akamanchi -
- Vilas Gaikar -
- Ramdas Gandhi -
- Navin Shah -
- Bhavesh Vora -
We do not have data on Aarti Drugs' shareholders